A trial involving HIV-tuberculosis in India: The minute particulars

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 7, 2010, Pages 652-654

  Vernon, Andrew ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

EDITORIAL; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; HUMAN; METHODOLOGY; MICROBIOLOGY; NOTE; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; INDIA; RIFAMPIN; TUBERCULOSIS;

EID: 77951933304     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200912-1822ED     Document Type: Editorial

References (17)

1. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon P, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, et al. Efficacy of a 6 vs. a 9-month intermittent treatment regimen in HIV-infected TB patients: a randomized clinical trial. Am J Respir Crit Care Med 2010(181):743-751.
2. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1959;21:51-144.
3. Khatri GR, Frieden TR. Controlling tuberculosis in India. N Engl J Med 2002;347:1420-1425.
4. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patientss with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-1206. (Pubitemid 46855463)
5. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999;353:1843-1847. (Pubitemid 29251017)
6. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al.; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173:350-356.
7. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;358:585. (Pubitemid 32378696)
8. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005;41:83-91.
9. Tuberculosis Research Centre, India. Comparing daily versus intermittent regimen of ATT (ethambutol, pyrazinamide, INH, rifampicin) in HIV with pulmonary tuberculosis (TB). Clinical trial entered at www.ClinicalTrials.Gov, as NCT00933790.
10. National AIDS Control Organisation. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure [Internet]. Accessed 5 December 2009. Available from: http://www.nacoonline.org/NACO/About- NACO/Policy--Guidelines
11. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009;6:e1000146.
12. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008;149:123-134. (Pubitemid 352008599)
13. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th edition. Available from: http://whqlibdoc.who.int/ publications/2010/9789241547833-eng.pdf
14. Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002;51:214-215.
15. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77.
16. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223. (Pubitemid 40116230)
17. Blake W. The holiness of minute particulars, from Jerusalem. Accessed online on December 2, 2009 at http://users.compaqnet.be/cn127848/blake/ collected/chap-29.html